**Abstract**

**Objective:** Recent progress in the development of tau-selective PET tracers enabled non-invasive visualization of neurofibrillary pathology in the human brain. The amount and spatial distribution of tau tracer binding in the brain is closely associated with neurodegeneration and cognitive symptom of dementia. Therefore, tau PET imaging is expected to be useful for tracking disease progression, assessing disease severity, and accurately predicting dementia prognosis. The purpose of this study was to assess the clinical usefulness of THK tau PET tracers.

**Methods:** Subjects with Alzheimer's disease, mild cognitive impairment and healthy controls (Number of each group is more than 10) underwent \[^18^F\]THK-5351 and \[^11^C\]PiB PET scans. Standard uptake value ratios between 50--60 minutes post injection for THK-5351 was calculated using the cerebellar cortex as a reference region.

**Results:** Subjects with mild cognitive impairment showed higher THK retention in the fusiform gyrus, inferior temporal and parietal cortices than healthy control subjects. Patients with Alzheimer's disease showed higher and more extensive neocortical THK retention than subjects with mild cognitive impairment. In some cognitively normal individuals, THK retention was mildly elevated in the inferior temporal area. THK retention in the parahippocampal and fusiform gyrus, inferior temporal and parietal cortices was correlated with clinical severity of dementia.

**Conclusion:** THK-5351 enables sensitive and selective detection of neurofibrillar pathology in Alzheimer's disease. Tau PET imaging with this tracer could be employed to study longitudinal tau deposition in normal aging and pathological process of Alzheimer's disease.
